Catalyst Pharmaceuticals, a biopharmaceutical company, agreed to invest $100m in Santhera Pharmaceuticals, a specialty pharmaceutical company. “We are extremely pleased to be entering into a partnership with Santhera on the vamorolone program and the prospect of delivering a potential therapy with a desirable profile for DMD patients. We believe this transaction provides us with a highly complementary drug candidate with outstanding clinical data that will accelerate our offerings of effective and innovative treatment advances to people living with rare neurological disorders. If approved, vamorolone would represent an important inflection point in our long-term growth strategy, further leveraging the company as a growing leader in rare neurological diseases. Upon closing the transaction, we will be well-positioned to capitalize on the synergies of our expanded and exceptional capabilities in preparation for the launch of vamorolone, which, assuming approval of the NDA by the PDUFA date, is anticipated to occur early in 2024. We look forward to collaborating with our partners who share our commitment to providing innovative new treatment advances to patients living with rare neurological disorders," Patrick J. McEnany, Catalyst Chairman and CEO.